CAS: 1973485-18-5

KDS-0071 is a novel antibiotic compound, which is derived from a fermentation process involving specific strains of actinobacteria. With a unique mechanism of action, it targets bacterial cell wall synthesis, effectively inhibiting the growth and proliferation of Gram-positive and select Gram-negative bacteria. KDS-0071 disrupts the cross-linking of peptidoglycan layers, leading to cell lysis and death of susceptible bacterial cells. The applications of KDS-0071 extend to both clinical and laboratory settings. In clinical environments, it is utilized in treating a variety of bacterial infections, particularly those resistant to conventional antibiotics. In research, it serves as a vital tool in microbiology for studying bacterial cell wall synthesis pathways and developing resistance mitigation strategies. The specificity and efficiency of KDS-0071 make it a critical resource in advancing our understanding of bacterial pathogenesis and designing new therapeutic approaches.

JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).

JAK1-IN-8